Clinical Trials Logo

Atopic Asthma clinical trials

View clinical trials related to Atopic Asthma.

Filter by:

NCT ID: NCT05098600 Completed - Clinical trials for Rheumatoid Arthritis

The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic

Start date: October 15, 2021
Phase:
Study type: Observational

The study series consists of three studies with the aim to assess the incidence, prevalence, risk factors, comorbidities and management of patients with alopecia areata in Czech Republic based on the patients and registry of a dermatology clinic of a metropolitan hospital.

NCT ID: NCT04728711 Completed - Atopic Asthma Clinical Trials

A Double Masked, Placebo Controlled, Single Center, Randomized Clinical Trial to Assess the Safety and Efficacy of Subjects With Mild Asthma Induced by the Bronchial Allergen Challenge (BAC)

Start date: January 9, 2021
Phase: Phase 2
Study type: Interventional

A Double Masked, Placebo Controlled, Single Center, Randomized Clinical Trial to Assess the Safety and Efficacy of ADX-629 in Subjects with Mild Asthma Induced by the Bronchial Allergen Challenge (BAC)

NCT ID: NCT04397081 Completed - Clinical trials for Human Papilloma Virus

Atopic Diseases & Human Papilloma Virus

Start date: August 1, 2019
Phase:
Study type: Observational [Patient Registry]

Cervical cancer is an important health problem in women. Human papillomavirus (HPV) is considered the primary etiological agent of cervical cancer worldwide. Cervical cancer screening methods are proved one of the few screening methods that are thought to decrease invasive cancer incidence and mortality. In our country, HPV screening is carried out free of charge by public health to women between the ages of 30-65 aim is to compare HPV screening results between women diagnosed with atopic disease and healthy women without a history of atopy.If HPV is detected more frequently in patients with atopy, it may be recommended to follow more closely in vaccination and screening programs. Therefore, our study was designed to evaluate whether HPV positivity is common in atopic women.

NCT ID: NCT03928431 Recruiting - Atopic Dermatitis Clinical Trials

Restoration of Microbiota in Neonates

RoMaNs
Start date: January 1, 2019
Phase: N/A
Study type: Interventional

The aim of the study is to examine the effect of exposure of cesarean section (CS) delivered neonates to a natural condition of birth, i.e. to the microbiota of the birth canal, on the acquisition of microbial genes during development of the microbiome at multiple body sites, immune system maturation and allergy risk in childhood

NCT ID: NCT03665701 Completed - Atopic Asthma Clinical Trials

Characterization of the Inhibitory Effects of Fevipiprant (QAW039) on Activation of Eosinophils and ILC2 Cells by Prostaglandin D2 Metabolites

18-03 EONOV
Start date: August 16, 2018
Phase: N/A
Study type: Interventional

The aim of this study is to draw blood from patients with well-defined atopic asthma that will be subsequently used in invitro experiments to investigate the activation potency of Prostaglandin D2 metabolites to the DP2 receptor in comparison to Prostaglandin D2. The inhibitory activity of a potent DP2 receptor antagonist, Fevipripant, shall be determined.

NCT ID: NCT03603522 Completed - Atopic Asthma Clinical Trials

Probiotics and Capsaicin Evoked Coughs

PCEC
Start date: July 16, 2019
Phase: N/A
Study type: Interventional

Cough in asthma is a very common and troublesome symptom in asthma, which predicts severity and poor prognosis. Previous studies have shown that asthmatics have an exaggerated cough response to capsaicin. Currently available asthma treatment is not designed to target the cough reflex directly, so this presents an unmet need for patients. The treatment being tested in this study is the commercially available over the counter oral probiotic BioGaia® DSM17938. Based on clinical and pre-clinical evidence, it is hypothesized that TRPV1 antagonism with BioGaia® DSM17938 will result in a reduction in capsaicin evoked coughs in patients with asthma.

NCT ID: NCT02758548 Completed - Atopic Asthma Clinical Trials

Determination of Accuracy in Measurement of Total Immunoglobulin E Using a Test Device in Atopic Subjects

Start date: March 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the accuracy of the Novel point of care test (POCT) total IgE assay in atopic patients. 120 patients with atopic conditions and approximately 40 healthy subjects will be enrolled. Fingerstick capillary blood samples will be collected and tested in the POCT device. Venous samples will be collected and sent to a reference laboratory for measurement of serum total IgE using the reference immunoassay method.

NCT ID: NCT02327234 Completed - Atopic Asthma Clinical Trials

Airway Response to Repeat Allergen Challenge and the Effect of Ibuprofen in Mild Atopic Asthma

Start date: December 2014
Phase: N/A
Study type: Interventional

The study will assess airway responses in mild atopic asthmatics undergoing repeat allergen challenge testing and will investigate whether ibuprofen changes the response.

NCT ID: NCT01890161 Completed - Atopic Asthma Clinical Trials

A Phase IIa Repeat Dose AXP1275 vs Placebo Cross-over Trial With Pulmonary Allergen Challenge in Adults With Asthma

Start date: August 2013
Phase: Phase 2
Study type: Interventional

This is the first study in human patients with asthma that the sponsor is conducting in order to evaluate if there are signals that the investigational medication, AXP1275, may be a safe and effective treatment for asthma. The results of this study may help the sponsor to design additional studies.

NCT ID: NCT01545245 Completed - Atopic Asthma Clinical Trials

Effects of Preventive Treatment for Respiratory Syncytial (RS) Virus Infection During Infancy on Later Atopic Asthma in Preterm Infants

Start date: July 2010
Phase: N/A
Study type: Observational

The primary objective of the study is to determine whether the incidence of atopic asthma after three years old may be suppressed in the children who were born as preterm infants and prophylactically treated with palivizumab for respiratory syncytial (RS) virus infections during the infancy. The secondary objective is to determine whether the incidence of recurrent wheezing after three years old may be suppressed in the children who were born as preterm infants and prophylactically treated with palivizumab for RS virus infections during the infancy.